A5102882727- Gastric Cancer Management and Outcomes
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Helicobacter pylori-related gastroenterology studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Esophageal and GI Pathology
- Colorectal Cancer Treatments and Studies
- Nutrition and Health in Aging
- Genetic factors in colorectal cancer
- Gastrointestinal disorders and treatments
- Esophageal Cancer Research and Treatment
- Multiple and Secondary Primary Cancers
- Inflammatory Biomarkers in Disease Prognosis
- Enhanced Recovery After Surgery
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Glycosylation and Glycoproteins Research
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Immune Cell Function and Interaction
- Erythropoietin and Anemia Treatment
- Delphi Technique in Research
Seoul National University Hospital
2025
Samsung Medical Center
2015-2024
Sungkyunkwan University
2015-2024
American Society of Safety Professionals
2023
American Society of Anesthesiologists
2020
Creative Commons
2020
Samsung (United States)
2018
Samsung Medison (South Korea)
2018
Ghent University Hospital
2018
Kim's Eye Hospital
2016
Purpose The ARTIST (Adjuvant Chemoradiation Therapy in Stomach Cancer) trial was the first study to our knowledge investigate role of postoperative chemoradiotherapy therapy patients with curatively resected gastric cancer D2 lymph node dissection. This designed compare treatment capecitabine plus cisplatin (XP) versus XP radiotherapy (XP/XRT/XP). Patients and Methods arm received six cycles (capecitabine 2,000 mg/m 2 per day on days 1 14 60 1, repeated every 3 weeks) chemotherapy. XP/XRT/XP...
The Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) trial tested whether the addition of radiotherapy to adjuvant chemotherapy improved disease-free survival (DFS) patients with D2-resected gastric cancer (GC).Between November 2004 and April 2008, 458 GC who received gastrectomy D2 lymph node dissection were randomly assigned either six cycles capecitabine cisplatin (XP) or two XP followed by chemoradiotherapy then additional (XPRT). This final update contains first publication overall...
Adjuvant chemotherapy and chemoradiotherapy are some of the standards care for gastric cancer (GC). The chemoRadioTherapy In Stomach Tumors (ARTIST) 2 trial compares two adjuvant regimens in patients with D2-resected, stage II or III, node-positive GC.The ARTIST compared, a 1:1:1 ratio, three regimens: oral S-1 (40-60 mg twice daily 4 weeks on/2 off) 1 year, (2 on/1 week plus oxaliplatin 130 mg/m2 every 3 (SOX) 6 months, SOX 45 Gy (SOXRT). Randomization was stratified according to surgery...
Abstract The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was designed to classify patients with metastatic based on clinical sequencing and focused eight different biomarker groups (RAS aberration, TP53 mutation, PIK3CA mutation/amplification, MET amplification, overexpression, all negative, TSC2 deficient, or RICTOR amplification) assign one of the 10 associated trials in second-line (2L) treatment. Capivasertib (AKT inhibitor), savolitinib (MET selumetinib (MEK...
OBJECTIVES: Few studies have compared the long-term outcomes of endoscopic resection and surgery. The aim this study was to compare with those surgery for early gastric cancer (EGC). METHODS: We reviewed prospectively collected data patients who had undergone (1,290 patients) or (1,273 EGC. To reduce effect selection bias, we performed a propensity score-matching analysis between two groups. primary outcome overall survival (OS). secondary were disease-specific survival, disease-free (DFS),...
In Brief Objective: Little is known about how quality of life (QOL) changes over time after gastrectomy. We prospectively examined QOL in Korean patients with gastric cancer curative resection. Background: As early detection and improved treatment have led to higher survival rates an increasing number long-term survivors, the importance has increased. Methods: Patients newly diagnosed cancer, who were expected undergo resection, studied. was assessed, using European Organization for Research...
Despite the benefits from adjuvant chemotherapy or chemoradiotherapy, approximately one-third of stage II gastric cancer (GC) patients developed recurrences. The aim this study was to develop and validate a prognostic algorithm for (GCPS) that can robustly identify high-risk group recurrence among patients. A multi-step gene expression profiling conducted. First, microarray archived paraffin-embedded tumor blocks used candidate genes (N = 432). Second, focused assay including robust clinical...
FGFR2 gene amplification, and resulting protein overexpression, is rare in gastric cancer patients, development of an accurate widely available method for mass screening to identify patients who may respond treatment with fibroblast growth factor receptor (FGFR) inhibitors important. We first screened 312 known copy number variations by FGFR2b immunohistochemistry using FPR2-D, isoform-specific antibody. Next, we performed on tissue microarrays from 1574 patients. Selected cases were...
Much attention has been paid to conversion therapy for stage IV gastric cancer, however, its operative comorbidities and survival benefit have not yet clarified. CONVO-GC-1, an international retrospective cohort study, was designed investigate the role of surgery in Japan, Korea, China. The rate complications primary endpoint overall (OS), according four-category criteria previously published (Gastric Cancer:19; 2016), analyzed as secondary endpoint. A total 1206 patients underwent after...
Abstract Background and Objectives The correlation between perioperative CEA, CA 19‐9, 72‐4 recurrence of gastric cancer has not been clarified. aim this study was to investigate the relationships cancer. Methods We retrospectively analyzed tumor markers Results In patients with early cancer, sensitivity postoperative 40.0, 5.6, 2.8%, respectively. And in advanced 100.0, 68.2, 51.3%, Multivariate analyses showed that an increase CEA independent prognostic factor recurrence. age >60 years,...
Programmed death-ligand 1 (PD-L1) is expressed in a subgroup of gastric cancers that may benefit from immunotherapy. Microsatellite instability-high (MSI-H) potential predictive factor for response to immunotherapy targeting the PD-1 or its ligand PD-L1. The relationship between PD-L1 expression and MSI-H status remains poorly understood. In this study, we investigated patients with cancer. We analyzed 78 cancer tissue samples using immunohistochemistry. was classified as on tumor cells...
// Han Sol Choi 1, 2, * , Sang Yun Ha 3, Hye-Mi Kim 2 Soo Min Ahn 3 Myung-Soo Kang 4, 5 Kyoung-Mee Gew 6 Joon Ho Lee Tae Sung Sohn Jae Moon Bae Eun-Suk 1 Samsung Biomedical Research Institute, Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department Laboratory Medicine and Genetics, Pathology Translational Genomics, 4 Advanced Institute for Health Sciences Technology (SAIHST), (SBRI), Center Future Sciences, Surgery, These author contributed equally to this work...
Abstract Background The indications for endoscopic dissection have been expanded to improve the quality of life patients with early gastric cancer (EGC). This study aimed develop a nomogram predict status lymph node metastasis aim avoiding unnecessary gastrectomies. Methods We reviewed clinicopathological data 10 579 who underwent curative resection EGC. was developed by multivariate analysis and evaluated external validation. Overall, disease-free recurrence-free survival were compared...
// Sangjeong Ahn 1, 6, * , Soomin 2, Michael Van Vrancken Minju Lee 1 Sang Yun Ha Hyuk 3 Byung-Hoon Min Jun Haeng Jae J. Kim Sunkyu Choi 4 Sin-Ho Jung Gew 5 Jun-Ho Tae Sung Sohn Moon Bae Kyoung-Mee 2 Department of Pathology & Translational Genomics, Samsung Medical Center, Sungkyunkwan University School Medicine, Seoul, Korea Center for Companion Diagnostics, Innovative Cancer Medicine Institute, Biostatistics and Clinical Epidemiology Surgery, 6 Present address: Pathology, Pusan National...
Genetic alterations are the starting point leading to numerous changes in clinical and pathologic features (phenotypes) of individual cancers; however, their inter-relationships gastric cancers (GC) unclear. We performed massive parallel sequencing 381 cancer-related genes compared results with findings 330 GC. High tumor mutation burden (TMB) accounted for 11% GC (n = 37) all 19 MSI-H GCs were high TMB. TMB was significantly more frequent intestinal-type by Lauren, higher host cellular...
Endoscopic resection of early gastric cancer is a relatively new and attractive treatment, but occasionally fails to remove all lesions completely. This study aimed elucidate clinicopathological factors that could be helpful in predicting residual tumour the surgical specimen after incomplete endoscopic submucosal dissection (ESD).Patients who underwent gastrectomy because ESD between August 2004 2008 were analysed. Clinicopathological characteristics reviewed retrospectively from...
The aim of the study was to develop a reliable and easy-to-use risk-scoring system (RSS) predict lymph-node metastasis (LNM) determine feasibility endoscopic submucosal dissection for mucosa-confined signet ring cell carcinomas (SRCs).Fewer LNM better survival rates have been reported early gastric SRCs compared with other undifferentiated cancers (EGCs).Data from 1544 patients were reviewed. Stepwise logistic regression analysis determined independent predictors LNM. Risk scores based on...